A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Essential hypertension; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 11 May 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
- 30 Sep 2010 Results were presented at the 23rd Scientific Meeting of the International Society of Hypertension.
- 01 May 2010 Results were presented at the 25th Annual Scientific Meeting of the American Society of Hypertension.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History